World-leading enzyme manufacturer Novozymes has entered a partnership with the US company Solae to develop and market new soy proteins with distinct functional and nutritional benefits, writes financial daily newspaper Børsen. Solae will handle development, production and marketing of the soy proteins, while Novozymes will use its enzyme technology to enrich the enzymes.
Peder Holk Nielsen, executive vice president and head of Novozymes' Enzyme Business says in a press release from Novozymes: "The partnership with Solae holds great potential and is a good example of how Novozymes' bioinnovation can be utilised in many areas, in this case to create new and healthy solutions for the food industry."
Soy proteins are added to many food products including infant formulas, meal replacement drinks, sport bars and beverages. CEO of Solae Torkel Rhenman comments: "Our new soy protein ingredients will work in a broader range of food applications, making it easier for consumers across the globe to choose healthy, great tasting food."
Headquartered in Bagsværd, a northern suburb of Copenhagen, Novozymes is the world’s largest and most diversified provider of industrial biotechnology, pioneering the replacement of chemicals with enzymes in a broad range of industries such as laundry detergents, animal feed and the biofuel industry. In 2007, the company generated sales of DKK 7.4bn (USD 1.35bn) and a net profit of DKK 1bn (USD 180m). Novozymes employs some 4,500 people, half of whom are based in Denmark.